利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.021 秒)

    RBM3 in colorectal cancer prognostics
    12.
    发明授权
    RBM3 in colorectal cancer prognostics 有权
    RBM3在结肠直肠癌预后中的作用

    公开(公告)号：US08728739B2

    公开(公告)日：2014-05-20

    申请号：US13210816

    申请日：2011-08-16

    申请人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström

    发明人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： C07K16/18 ,  A61K31/7068 ,  A61K39/39533 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/3038 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57419 ,  A61K2300/00

    摘要： The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

    摘要翻译： 本发明提供了用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，例如方法，其中第一组受试者的预后优于第二组受试者的预后 。 该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白或RBM3 mRNA分子的量，并确定对应于评估量的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

    PODXL protein in colorectal cancer
    15.
    发明授权
    PODXL protein in colorectal cancer 有权
    PODXL蛋白在结肠直肠癌中的表达

    公开(公告)号：US08999656B2

    公开(公告)日：2015-04-07

    申请号：US13456354

    申请日：2012-04-26

    申请人： Karin Jirström ,  Mathias Uhlén ,  Fredrik Pontén

    发明人： Karin Jirström ,  Mathias Uhlén ,  Fredrik Pontén

    IPC分类号： G01N33/574 ,  C07K16/30

    CPC分类号： G01N33/57419 ,  C07K16/22 ,  C07K16/3046 ,  C07K2317/76 ,  G01N2333/705 ,  G01N2333/90216 ,  G01N2800/52 ,  G01N2800/56

    摘要： The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.

    摘要翻译： 本公开提供了一种用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤： ：a）评估早先从受试者获得的样品的至少一部分中的PODXL蛋白的量，并确定与评估量相对应的样品值; b）将来自步骤a）的所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）认定所述对象属于所述第二组; 并且如果所述样本值小于或等于所述参考值，则c2）断定所述对象属于所述第一组。 还提供了相关用途，手段和治疗方法。

    SYSTEM AND METHOD FOR IDENTIFYING AND AUTHENTICATING COUNTERFEITING ARTICLES
    17.
    发明申请
    SYSTEM AND METHOD FOR IDENTIFYING AND AUTHENTICATING COUNTERFEITING ARTICLES 有权

    公开(公告)号：US20210124964A1

    公开(公告)日：2021-04-29

    申请号：US16660864

    申请日：2019-10-23

    申请人： Fredrik Pontén

    发明人： Fredrik Pontén

    IPC分类号： G06K9/18 ,  G06K9/46 ,  G06F21/44

    摘要： A system and method for identifying and authenticating a counterfeit article using digital fingerprints are disclosed. The system comprises a server with a processor and memory, and a database. The memory is configured to store a set of modules executable by the processor. The set of modules include, but not limited to, a digital image acquisition module, a comparison module, and a decision module. The digital image acquisition module is configured to extract analog identification indicium of the article from one or more images. The comparison module is configured to compare analog identification indicium with actual analog identification indicium of the article. The decision module detects the authenticity of the article based on the comparison results. The system further comprises an anti-counterfeiting network verification system in communication with the server, configured to securely protect the actual analog identification indicium of the article from unauthorized access and other potential crimes.

    Means and Method for Ovarian Cancer Prognosis
    19.
    发明申请
    Means and Method for Ovarian Cancer Prognosis 审中-公开
    卵巢癌预后的手段和方法

    公开(公告)号：US20120058202A1

    公开(公告)日：2012-03-08

    申请号：US13201740

    申请日：2010-02-16

    申请人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström ,  Donal J. Brennan

    发明人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström ,  Donal J. Brennan

    IPC分类号： A61K31/555 ,  C12Q1/68 ,  C40B30/04 ,  C07K16/18 ,  C07K14/47 ,  C07K7/06 ,  C07K4/12 ,  G01N33/574 ,  A61P35/00

    CPC分类号： G01N33/689 ,  C07K14/4748 ,  G01N33/5743

    摘要： There is provided a method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined refer-ence value; and if said sample value is higher than said ref-erence value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the sub-ject belongs to the second group. Related peptides, affinity ligands, uses and further methods are also provided.

    摘要翻译： 提供了一种用于确定具有卵巢癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤： a）评估早期从受试者获得的样品的至少一部分中的RBM3蛋白的量，并确定对应于评估量的样品值; b）将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）得出结论，所述受试者属于第一组; 并且如果所述样本值小于或等于所述参考值，则c2）推断子项目属于第二组。 还提供了相关肽，亲和配体，用途和其它方法。